Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

60 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Health-related quality of life outcomes with prasugrel among medically managed non-ST-segment elevation acute coronary syndrome patients: Insights from the Targeted Platelet Inhibition to Clarify the Optimal Strategy to Medically Manage Acute Coronary Syndromes (TRILOGY ACS) trial.
Kaul P, Ohman EM, Knight JD, Anstrom KJ, Roe MT, Boden WE, Hochman JS, Gašparović V, Armstrong PW, McCollam P, Fakhouri W, Cowper P, Davidson-Ray L, Clapp-Channing N, White HD, Fox KA, Prabhakaran D, Mark DB; TRILOGY ACS Investigators. Kaul P, et al. Among authors: fakhouri w. Am Heart J. 2016 Aug;178:55-64. doi: 10.1016/j.ahj.2016.03.017. Epub 2016 Apr 16. Am Heart J. 2016. PMID: 27502852 Clinical Trial.
Radiographic progression can still occur in individual patients with low or moderate disease activity in the current treat-to-target paradigm: real-world data from the Dutch Rheumatoid Arthritis Monitoring (DREAM) registry.
Ten Klooster PM, Versteeg LGA, Oude Voshaar MAH, de la Torre I, De Leonardis F, Fakhouri W, Zaremba-Pechmann L, van de Laar M. Ten Klooster PM, et al. Among authors: fakhouri w. Arthritis Res Ther. 2019 Nov 12;21(1):237. doi: 10.1186/s13075-019-2030-8. Arthritis Res Ther. 2019. PMID: 31718678 Free PMC article. Clinical Trial.
Cost-Effectiveness of a JAK1/JAK2 Inhibitor vs a Biologic Disease-Modifying Antirheumatic Drug (bDMARD) in a Treat-to-Target Strategy for Rheumatoid Arthritis.
Van De Laar CJ, Oude Voshaar MAH, Fakhouri WKH, Zaremba-Pechmann L, De Leonardis F, De La Torre I, Van De Laar MAFJ. Van De Laar CJ, et al. Clinicoecon Outcomes Res. 2020 Apr 15;12:213-222. doi: 10.2147/CEOR.S231558. eCollection 2020. Clinicoecon Outcomes Res. 2020. PMID: 32346301 Free PMC article.
60 results